Fox Run Management L.L.C. Invests $1.23 Million in Kenvue Inc. $KVUE

Fox Run Management L.L.C. purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 58,836 shares of the company’s stock, valued at approximately $1,231,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Pittenger & Anderson Inc. bought a new stake in Kenvue during the 1st quarter valued at $30,000. Trust Co. of Vermont boosted its holdings in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after acquiring an additional 1,150 shares during the period. TruNorth Capital Management LLC purchased a new position in shares of Kenvue in the first quarter valued at $36,000. Truvestments Capital LLC purchased a new position in shares of Kenvue in the first quarter valued at $37,000. Finally, Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after purchasing an additional 1,287 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Up 2.6%

Shares of KVUE opened at $16.90 on Friday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The company has a market capitalization of $32.37 billion, a P/E ratio of 22.53, a P/E/G ratio of 2.46 and a beta of 0.71. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The firm’s 50 day simple moving average is $16.76 and its 200 day simple moving average is $20.28.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 4.9%. Kenvue’s payout ratio is 110.67%.

Analyst Upgrades and Downgrades

Several research analysts have commented on KVUE shares. Citigroup cut their target price on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Zacks Research raised shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. Edward Jones lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Finally, Barclays lowered their target price on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $20.17.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.